Imbruvica
ibrutinib · Bruton's Tyrosine Kinase (BTK) Inhibitor
Indications & Uses
Adult patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia, and chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
Contraindications
None.
Side Effects & Warnings
Hemorrhage, cardiac arrhythmias (atrial fibrillation, ventricular arrhythmia), hypertension, infections, cytopenias, second primary malignancies, and diarrhea.
Drug & Dietary Interactions
Avoid coadministration with strong CYP3A inhibitors or inducers; grapefruit products and Seville oranges must be avoided.
Regulatory & Prescribing Information
FDA Approved NDA 205552.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.